The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.